Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (January 2025)
22 slides from Adma Biologics's investor presentation, Jan 13, 2025
Slide 1: Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2025 NASDAQ: ADMA
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitati
Slide 3: Who We Are
Who We Are NASDAQ: ADMA
Slide 4: Who We Are: An Innovative Specialty Biologics Company
Who We Are: An Innovative Specialty Biologics Company ADMA Biologics ian end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty biologics for the prevention and treatment of infectious diseases in the immune compromised and other patients at ri
Slide 5: Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology
Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology Unique visibility of ~9-12+ months out given end-to-end production cycle ADMA’s end-to-end manufacturing capabilities enable efficiency, visibility and a competitive advantage MANUFACTURING & PRODUCTION World-clas
Slide 6: Vertical Integration: Plasma Collection Centers Essential to Ensure Raw Material Supply
Vertical Integration: Plasma Collection Centers are Essentialto Ensure Raw Material Supply to Produce IG 10 FDA-Approved BioCenters in Maryland, Tennessee, Louisiana, North Carolina, South Carolina and Georgia ADMA BioCenters collects hyperimmune & normal source plasma – allows for internal control
Slide 7: US IG Landscape
US IG Landscape NASDAQ: ADMA
Slide 8: Fast Growing & Highest Margin Company in a Large and Expanding IG Market
Fast Growing & Highest Margin Company in a Large and Expanding IG Market Source: (1) Source: Marketing Research Bureau, 2023 U.S. Fractionation Market Report, ADMA internal analysis (2) Centers for Disease Control, National Institute of Health In a 40-year study of 473 patients with PI on standard I
Slide 9: ASCENIV – ADMA's Unique IG Offering
ASCENIVTM – ADMA’s Unique IG Offering THE PRODUCTION OF ASCENIV ONLY IG PRODUCT MANUFACTURED USING PATENTED DONOR SCREENINGAND PLASMA POOLING METHODS (1) IN A 1-YEAR STUDY OF PATIENTS WITH PI, ASCENIV reported zero serious bacterial infections (SBIs)* *SBIs were defined as a rate of <1.0 cases of ba
Slide 10: ASCENIV – Making a Positive Difference for Patients with PI
ASCENIVTM – Making a Positive Difference for Patients with PI We do what we do because patients are counting on us 1. ADMA Biologics patents issued 9,107,906 – 9,714,283 – 9,815,886 2. ASCENIV Prescribing Information, ADMA Biologics, 2019 Compelling Real-World Patient Testimonials Testimonial Highli
Slide 11: High Demand for ASCENIV in a Sizable, Refractive TAM
(TAM): Total Adressable Market ~10% (25k patients) 250,000+ Diagnosed PI Patients & Growing High Demand & Growth Opportunity for ASCENIV Within the Broader IG Market Patients with recurrent, breakthroughinfections on standard IG therapy cycle through multiple lines of products A sub-set of PI patien
Slide 12: Established distribution network and channel partners cover targeted call-points
Established distribution network and channel partners comprehensively cover targeted call-points and sites of care Distribution channel is well defined Inpatients – hospital based Outpatients – infusion center / physician office / homecare Established distribution partners handle cold-chain products
Slide 13: Upside & Growth Opportunities
Upside & Growth Opportunities NASDAQ: ADMA
Slide 14: Production Yield Enhancement: Significant Upside Potential
Regulatory filing successfully submitted to the FDA; potential mid-2025 approval Demonstrated ability at the commercial production scale to potentially realize ~20% additional IG production yields from same quantities of starting plasma Significant upside potential from production yield enhancement,
Slide 15: SG-001: Potential Upside Through New Product Pipeline Program
SG-001: Potential Upside Through New Product Pipeline Program Issued IP for commercial product to screen hyperimmunedonors, tailor compositions and form plasma pools. IP protectionthrough 2035 Attractive new product and label expansion opportunities for specialty IGs targeting patient populations wi
Slide 16: Senior Leadership
Senior Leadership NASDAQ: ADMA
Slide 17: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors NAME SELECTED CURRENT OR PAST AFFILIATIONS Dr. Jerrold GrossmanFounder & Vice Chairman Lawrence GuiheenDirector Steven ElmsChairman Young Kwon, Ph.D.Director Alison FingerDirector Kaitlin KestenbergCOO & SVP Compliance Brad TadeCFO & Treasurer Adam
Slide 18: Financials
Financials NASDAQ: ADMA
Slide 19: Rapidly growing revenue and earnings growth, with uniquely durable asset base
Rapidly growing revenue and earnings growth, with uniquely durable asset base $1B+ annual revenue opportunityprior to 2030 2025 forecasted Adjusted EBITDA margins of ~45% Significant ongoing margin expansion anticipated to 2030 and thereafter ~45% adj. EBITDA Margin ~50% adj. EBITDA Margin Revenue A
Slide 20: Financial Overview
Financial Overview Financial Overview Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 Revenues $119.8M $67.3M Gross Profit $59.7M $24.7M Adjusted EBITDA(1) $45.4M $12.7M Net Income $35.9M $2.6M Cash and cash equivalents $86.7M $74.2M Total assets $390.6M $349.0M Total lia
Slide 21: Appendix - Non-GAAP Reconciliation
Appendix - Non-GAAP Reconciliation (1) Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, please see the Company’s earnings releases and SEC filings, as well as a reconciliation in the appendix (In US Millions) 3Q24 2Q24 1Q24
Slide 22: ADMA Investment Highlights
ADMA Investment Highlights Source: (1) Source: ADMA Company Estimates; Refractive; comorbid immunocompromised PI patients. SMART: Structural Demand, Manufacturing Optimizations, Advanced Tech, Raw Material Supply, Top-Tier Growth Outlook Top-tier revenue and earnings growth, unique asset durability,
ADMA Biologics — Investor Presentation (January 2025) on 6ix